- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07607730
Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation (RT-PWS)
Adapting a Group Intervention for Emotion Dysregulation in Prader-Willi Syndrome
The goal of this study is to help teens with Prader-Willi Syndrome (PWS) and their families learn practical strategies for managing issues like irritability, meltdowns, and anxiety. The main objective of the study is:
To adapt current Regulating Together materials to create an outpatient group program for emotion dysregulation in Prader-Willi Syndrome (PWS) that will improve psychosocial outcomes for youth with PWS.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Up to ten children with Prader-Willi Syndrome (PWS) ages 13 to 17.5 years and their caregivers will be enrolled in the study. This study is being done to develop and test a behavior therapy to help teenagers with PWS calm their emotions. Participants will complete assessments at five time points:
Screening (T1); Week 0: Baseline visit (T2); Week 5: Post Active Treatment (T3); Week 10: 5 week follow-up (T4); and Week 15: 10 week follow-up (T5). Participants will receive 5 weeks of intervention, twice per week, following the T2 visit.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Grayson Manley, RN
- Numero di telefono: 816-816-6967
- Email: gmanley@cmh.edu
Luoghi di studio
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- Children's Mercy
-
Contatto:
- Grayson Manley, RN
- Numero di telefono: 816-816-6967
- Email: gmanley@cmh.edu
-
Contatto:
- Walker McKinney, PhD
- Numero di telefono: 816-234-3656
- Email: wsmckinney@cmh.edu
-
Investigatore principale:
- Walker McKinney, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
Descrizione
Child Participant Inclusion Criteria:
- Ages 13-17.5 years
- Confirmed genetic diagnosis of Prader-Willi Syndrome
- Fluent in spoken English
- Adolescent's use of flexible phrase speech or greater
- Meeting clinically significant emotional dysregulation criteria
- Willing to participate in weekly 90-minute group sessions
- Family is willing to keep prescribed psychiatric medication and outside behavioral interventions stable
- Parent, guardian, or legally authorized representative must provide written permission on behalf of the participant
Child Participant Exclusion Criteria:
- Initiation of new psychosocial intervention within 30 days prior to first day of treatment
- Presence of physical aggression in the adolescent directed towards a peer outside the home that resulted in injury within 30 days prior to screening
- Presence of comorbid major neuropsychiatric illness warranting other treatment approaches
- Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss
Caregiver Inclusion Criteria:
- Age ≥ 18 years
- Lives and cares for their child with PWS for > 50% of the year
- Fluent in spoken English
- Willing to participate in twice weekly 90-minute sessions, including one virtual session weekly
Caregiver Exclusion Criteria:
-Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Teens with Prader-Willi Syndrome and their caregiver
Participants will receive Regulating Together - the emotion dysregulation intervention
|
Regulating Together is the original curriculum developed for autistic youth that uses evidence-based therapeutic strategies including relaxation techniques, parent management training, and mindfulness to help regulate emotions.
This study will adapt the original Regulating Together curriculum to focus on behavioral interventions to treat emotion dysregulation in Prader-Willi Syndrome.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Emotion Dysregulation Inventory - Reactivity
Lasso di tempo: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
The Emotion Dysregulation Inventory consists of two subscales.
We will use the Reactivity subscale which captures poorly regulated negative emotional responses and a dysphoria subscale characterized by increased negative affect and lack of motivation.
Minimum raw score: 0; Maximum raw score: 96; Higher scores reflect higher emotional reactivity.
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Caregiver and Adolescent Readiness and Satisfaction Surveys
Lasso di tempo: From enrollment to end of follow up at 15 weeks
|
We will assess acceptability as reflected in the average caregiver and adolescent satisfaction rating measured using two study-specific measures.
Caregivers will complete the Caregiver Readiness and Satisfaction Survey (CRS) and adolescents will complete the Adolescent Readiness and Satisfaction Survey (ARS).
|
From enrollment to end of follow up at 15 weeks
|
|
Clinician Global Impressions - Improvement (CGI-I)
Lasso di tempo: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
A trained, independent clinician will rate the CGI at T3 and T5.
The CGI-I provides a qualitative measure of treatment response through a rating from 1=very much improved to 7=very much worse.
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Emotion Regulation Skills Test
Lasso di tempo: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
A child self-report measure created for Regulating Together to measure knowledge of skills taught to manage emotion dysregulation.
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depression Scales (Parent-Proxy)
Lasso di tempo: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
Caregiver-report measures to measure change in internalizing symptoms.
For both measures: minimum raw value: 13; maximum raw value: 65; higher scores reflect greater anxiety/depression
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Aberrant Behavior Checklist, 2nd Edition (ABC-2)
Lasso di tempo: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
Irritability subscale; a caregiver-report measures to measure change in irritability and related challenging behaviors.
Minimum score: 0; Maximum score: 45; higher scores reflect greater irritability
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Parenting Stress Index, 4th Edition, Short Form
Lasso di tempo: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
A caregiver-report questionnaire measuring the magnitude of stress in the parent-child system.
Minimum score: 36; Maximum score: 180; Higher scores reflect greater parental stress
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Walker McKinney, PhD, Children's Mercy
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Comportamento motorio aberrante nella demenza
- Disturbi dell'imprinting
- Manifestazioni neurologiche
- Malattie del sistema nervoso
- Disordini mentali
- Disturbi della nutrizione
- Malattie genetiche, congenite
- Ipernutrizione
- Segni e sintomi, Digestivo
- Sintomi comportamentali
- Manifestazioni neurocomportamentali
- Anomalie congenite
- Anomalie multiple
- Sovrappeso
- Disabilità intellettuale
- Obesità
- Disturbi cromosomici
- Malattie e anomalie congenite, ereditarie e neonatali
- Condizioni patologiche, segni e sintomi
- Comportamento
- Malattie nutrizionali e metaboliche
- Segni e sintomi
- Comportamento sociale
- Disturbi d'ansia
- Depressione
- Aggressione
- Sindrome di Prader-Willi
- Iperfagia
Altri numeri di identificazione dello studio
- STUDY00004042
- 1568503 (Altro numero di sovvenzione/finanziamento: Foundation for Prader-Willi Research)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Sindrome di Prader-Willi
-
Aardvark Therapeutics, Inc.SospesoIperfagia | Sindrome di Prader-Willi | Iperfagia nella sindrome di Prader-WilliStati Uniti, Australia, Regno Unito, Canada, Corea del Sud
-
University Hospital, ToulouseCompletatoSindrome di Prader WilliFrancia
-
University Hospital, ToulouseCompletato
-
Shaare Zedek Medical CenterSconosciutoSindrome di Prader Willi
-
University of FloridaNational Institutes of Health (NIH)Completato
-
Duke UniversityCanadian Institutes of Health Research (CIHR); National Institutes of Health... e altri collaboratoriCompletatoObesità | Sindrome di Prader WilliStati Uniti
-
Samsung Medical CenterCompletatoObesità | Sindrome di Prader Willi
-
California State University, FullertonUniversity of FloridaSconosciutoObesità infantile | Sindrome di Prader WilliStati Uniti
-
Samsung Medical CenterCompletatoObesità | Sindrome di Prader Willi
-
SanionaCompletatoDiagnosi genetica confermata della sindrome di Prader-WilliCechia, Ungheria
Prove cliniche su Regulating Together group therapy
-
Karadeniz Technical UniversityCompletatoEmodialisi | Solitudine | Felicità | Adattamento | Terapia assistita da animali | SintomoTacchino